Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18802024 | 0.89 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL30443722 | 0.89 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL30443948 | 0.89 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL15538978 | 0.89 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL16795853 | 0.89 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL18802233 | 0.84 | CYP2C19 (0.44) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL30443706 | 0.84 | CYP2C19 (0.44) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL30445110 | 0.84 | CYP2C19 (0.44) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL17093405 | 0.84 | CYP2C19 (0.44) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 | |
| SCHEMBL15550468 | 0.84 | CYP2C19 (0.44) | HTR2CHTR2AHTR2BCYP2C19SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107548473-A | Photoresists with Enhanced Sensitivity | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2018-01-05 | — | — | CN | disclosed |
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7414052-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1730127-B1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730127-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth, A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097761-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | HTR2C 36/4885HTR2A 58/4885HTR2B 77/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | HTR2C 36/4885HTR2A 58/4885HTR2B 77/4885 |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | HTR2C 36/4885HTR2A 58/4885HTR2B 77/4885 |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | HTR2C 38/4885HTR2A 76/4885HTR2B 85/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | HTR2C 36/4885HTR2A 58/4885HTR2B 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.